Targeting LIN28: a new hope in prostate cancer theranostics

Future Oncol. 2021 Oct;17(29):3873-3880. doi: 10.2217/fon-2021-0247. Epub 2021 Jul 15.


The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.

Keywords: LIN28A; LIN28B; biomarker; prostate cancer; theranostic.

Publication types

  • Review

MeSH terms

  • Humans
  • Male
  • Molecular Targeted Therapy*
  • Precision Medicine*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • RNA-Binding Proteins / metabolism*


  • LIN28B protein, human
  • RNA-Binding Proteins